Newsletter

Promising Clinical Trial Results From Flex Pharma

On November 6, Flex Pharma Inc. (FLKS) reported positive stage 2 clinical trial results for a new drug to treat cramps and spasticity associated with a variety of neurological disorders. Positive topline data for FLX-787 indicates that significant improvement of pain and cramping is possible for those suffering from multiple sclerosis (MS), amyotrophic lateral sclerosis […]

0Comments

October 2017 Scorecard

The scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October 2017 Scorecard Number of Signals 22 Percent Correct – Next Open to 5-day Peak 95.5% Avg Increase – Next Open to 5-day Peak 7.8% Other stats: Number of signals over $10/share 15 Number of […]

0Comments

AbbVie Reports Promising Phase 3 Clinical Trial Results

AbbVie (ABBV), in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced detailed results from two phase 3 clinical trial extension studies on November 1. The studies were analyzing the long-term efficacy and safety of Elagolix, a drug for the managing the pain associated with endometriosis. The results showed no increased safety concern after twelve months along […]

0Comments

September 2017 Scorecard

The scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: September 2017 Scorecard Number of Signals 34 Percent Correct – Next Open to 5-day Peak 100% Avg Increase – Next Open to 5-day Peak 11.4% Other stats: Number of signals over $10/share 21 Number of […]

0Comments

FDA Accepts Application for Investigational New Drug From Sangamo and Bioverativ

On October 2, Sangamo Biosciences (SGMO) and Bioverativ Inc. (BIVV) announced that the FDA accepted their application for an investigational new drug (IND). The drug, ST-400, is a gene-edited cell therapy candidate for people with transfusion-dependent-beta-thalassemia. There are about 100,000 patients being treated worldwide for this disease, which requires frequent blood transfusions.   Rocket Tickers […]

0Comments

Akebia Reports Successful Clinical Trial Results

On September 26, Akebia Therapeutics (AKBA) reported positive results from a phase 2 clinical trial of the drug Vadadustat. The study results came from Japanese patients with anemia associated with non-dialysis chronic kidney disease and confirmed prior findings.   Rocket Tickers detected the event and sent out an alert at 7:00 am. The next trade […]

0Comments

ZGNX Climbs on Clinical Trial Results

On September 29, Zogenix (ZGNX) reported positive results from its phase 3 clinical trial for the drug ZX008. The drug treats a rare form of epilepsy known as Dravet Syndrome.   Rocket Tickers caught the news at 7:00 am and sent out a level 2 alert. The stock price immediately surged but then faded after […]

0Comments

Alnylam Pharmaceuticals Reports Clinical Trial Success

On September 20, Alnylam Pharmaceuticals (ALNY) reported exciting stage 3 clinical trial results. Its drug, patisiran, treats a rare nerve disorder called familial amyloid polyneuropathy. Alnylam will seek regulatory approval for patisiran later this year. Rocket Tickers sent out a level 2 alert at 7 am, and the next trade was at $93.50. The price […]

0Comments

LCI Receives FDA Approval for New Drug

Lannett Company (LCI) announced on September 27 that is had received FDA approval for a new drug. The Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg are the therapeutic equivalent to the drug Percocet. U.S. sales of Oxycodone and Acetaminophin tablets USP, 5 mg/325 mg and 10 mg/325 mg totaled around […]

0Comments

Latest of Knowledge Center